ClinicalTrials.gg
CompletedNCT05218655Updated Dec 22, 2025Results posted

A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease

A Phase 3 interventional study of Vatiquinone in Inherited Mitochondrial Disease, sponsored by PTC Therapeutics. Completed at 26 sites in 7 countries. Per ClinicalTrials.gov, last updated 2025-12-22.

Sponsored by PTC Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 14 studies in Leigh Disease with a site in United States — 6 open to participants now, 6 under way, none of them phase 3. Leigh Disease · United States.

Started
2022
with 1 other
Phase 3
Only one
of the 14
Registered
12th of 14
by date
Lead sponsor
5 of 14
PTC Therapeutics

Among the 14 studies in Leigh Disease with a site in United States, this one is one of 2 that started in 2022, is the only one in phase 3, and was the 12th registered.

Leigh Disease

20 studies on the registry are indexed under Leigh Disease; 9 are open to participants now.

Browse Leigh Disease studies →

Open to participants now

6 of the 14 studies in Leigh Disease with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Leigh Disease studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 6 take children under 18; 2 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Leigh Disease with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan.

The study will continue until vatiquinone becomes commercially available or the program is terminated.

03

Conditions studied

  • Inherited Mitochondrial Disease

Keywords

  • Leigh syndrome
  • Alpers Syndrome
  • mitochondrial encephalomyopathy
  • MELAS
  • MERRF
  • PCH6
  • refractory epilepsy
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with inherited mitochondrial disease including Leigh syndrome, Alpers syndrome, mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), myoclonic epilepsy with ragged-red fibers (MERRF), pontocerebellar hypoplasia type 6 (PCH6), or other mitochondrial disease who participated in a previous vatiquinone clinical study or treatment plan.
  • Women of must have a negative pregnancy test at screening/baseline and agree to abstinence or the use of at least 1 of the highly effective forms of as specified in the protocol (with a failure rate of \<1% per year when used consistently and correctly). Highly effective contraception or abstinence must be continued for the duration of the study, and for up to 30 days after the last dose of study drug.
  • Fertile men who are sexually active with women of childbearing potential and who have not had a vasectomy, must agree to use a barrier method of birth control during the study and for up to 30 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Current participation in any other interventional study.
  • Pregnancy or breast feeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Vatiquinone

    Participants will receive vatiquinone oral solution (100 milligrams \[mg\]/milliliter \[mL\]), up to 400 mg, administered orally or via feeding tube 3 times daily (TID).

    Drug: Vatiquinone

Interventions

  • Vatiquinone will be administered per dose and schedule specified in the arm description.

    Also known as: PTC743

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included both serious adverse events (SAEs) and non-serious AEs. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug and within 30 days of the date of the last dose of treatment. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

    Time frame: Baseline (Day 1) up to 30 days after last dose of study drug (956 days)

07

Results

Posted Dec 22, 2025
Limitations and caveats
The study was terminated early as PTC discontinued clinical development of vatiquinone for this indication based on prior clinical study results.

Participant flow

Participant flow — Overall Study
MilestoneVatiquinone
Started101
Received at least 1 dose of study drug101
Completed0
Not completed101
Withdrew: Adverse event6
Withdrew: Sponsor's decision85
Withdrew: Death1
Withdrew: Lost to follow-up3
Withdrew: Withdrawal by subject3
Withdrew: Other than specified3

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. AEs included both serious adverse events (SAEs) and non-serious AEs. A TEAE was defined as an AE that had an onset date or date of worsening on or after the first dose of study drug and within 30 days of the date of the last dose of treatment. A summary of other non-serious AEs and all SAEs, regardless of causality is located in the 'Reported AE section'.

Time frame:
Baseline (Day 1) up to 30 days after last dose of study drug (956 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
ParticipantsVatiquinone
Number of Participants With Treatment-emergent Adverse Events (TEAEs)91

Adverse events

Collected over Baseline (Day 1) up to 30 days after last dose of study drug (956 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vatiquinone7/101 (6.9%)45/101 (44.6%)59/101 (58.4%)
Most frequent serious events
Showing 10 of 62
Most frequent serious events
EventVatiquinone
Acute respiratory failureRespiratory, thoracic and mediastinal disorders11/101
PneumoniaInfections and infestations10/101
VomitingGastrointestinal disorders4/101
COVID-19Infections and infestations3/101
Urinary tract infectionInfections and infestations3/101
Status epilepticusNervous system disorders3/101
Generalised oedemaGeneral disorders2/101
BronchitisInfections and infestations2/101
InfluenzaInfections and infestations2/101
Lower respiratory tract infectionInfections and infestations2/101
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVatiquinone
Upper respiratory tract infectionInfections and infestations14/101
COVID-19Infections and infestations13/101
PyrexiaGeneral disorders12/101
VomitingGastrointestinal disorders11/101
Urinary tract infectionInfections and infestations9/101
SeizureNervous system disorders9/101
NasopharyngitisInfections and infestations7/101
DiarrhoeaGastrointestinal disorders6/101
PneumoniaInfections and infestations6/101
Respiratory tract infectionInfections and infestations6/101

Baseline characteristics

Safety population included all participants who received at least 1 dose of vatiquinone in the study.

Age, Continuous
Age, Continuous(years)Vatiquinone
Mean15.5 ± 11.56
Sex: Female, Male
Sex: Female, Male(Participants)Vatiquinone
Female49
Male52
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vatiquinone
Race — American Indian/Alaska Native1
Race — Asian8
Race — Black/African American2
Race — White83
Race — Other1
Race — Unknown1
Race — Missing5
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Vatiquinone
Ethnicity — Hispanic or Latino9
Ethnicity — Not Hispanic or Latino86
Ethnicity — Not Reported3
Ethnicity — Unknown2
Ethnicity — Missing1
08

Study locations

26 sites
  • University of California, San Diego Altman Clinical and Translational Research Institute
    La Jolla, California 92037, United States
  • Stanford University
    Stanford, California 94305, United States
  • Yale Medicine
    New Haven, Connecticut 06511, United States
  • Children's National
    Washington D.C., District of Columbia 20010, United States
  • Child Neurology Center of Northwest Florida
    Gulf Breeze, Florida 32561, United States
  • The Johns Hopkins University
    Baltimore, Maryland 21205, United States
  • Columbia University Medical Center - CUMC
    New York, New York 10032, United States
  • Akron Children's Hospital
    Akron, Ohio 44308, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Children's Hospital of Philadelphia - CHOP
    Philadelphia, Pennsylvania 19104, United States
  • Medical University of South Carolina - MUSC
    Charleston, South Carolina 29425, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • UT Health The University of Texas
    Houston, Texas 77030, United States
  • Seattle Children Hospital
    Seattle, Washington 98105, United States
  • Chu Angers
    Angers, 49933, France
  • CHU Montpellier - Hopital Saint-Eloi
    Montpellier, 34295, France
  • Hopital Necker-Enfants Malades
    Paris, 75015, France
  • Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67000, France
  • Ospedale Pediatrico Bambino Gesù
    Roma, 00165, Italy
  • PTC Clinical Site
    Japanese City, Japan
  • Instytut Pomnik - Centrum Zdrowia Dziecka
    Warsaw, 04-730, Poland
  • Hospital Sant Joan de Déu
    Barcelona, 08950, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28003, Spain
  • Hospital Ruber Internacional
    Madrid, 28034, Spain
  • Great Ormond Street Hospital for Children NHS Foundation Trust
    London, WC1N 3JH, United Kingdom
  • The Newcastle Upon Tyne Hospitals NHS Foundation Trust
    Newcastle upon Tyne, NE1 4LP, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2022 to primary completion in Apr 2025, 33 months.

Results were first posted in Dec 2025, 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 19, 2022
First posted
Feb 1, 2022
StartActual
Jun 22, 2022
Primary completionActual
Apr 15, 2025
CompletionActual
Apr 15, 2025
Results first posted
Dec 22, 2025
Last update
Dec 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05218655
Lead sponsor
PTC Therapeutics
Responsible party
Sponsor
First posted
Feb 1, 2022
Start date
Jun 22, 2022
Primary completion
Apr 15, 2025
Completion
Apr 15, 2025
Results posted
Dec 22, 2025
Last update
Dec 22, 2025

Study contacts

Vinay Penematsa, MD
study director · PTC Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Alpha-tocotrienol quinone

Start the discussion